About IGI Laboratories (NYSE:IG)
IGI Laboratories, Inc. is a specialty generic pharmaceutical company. Under its IGI label, the Company sells generic topical pharmaceutical products that are bioequivalent to their brand name counterparts. The Company provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. The Company has two platforms for growth: developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its current contract manufacturing and formulation services business. The Company also develops, manufactures, fills and packages topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as the OTC and cosmetic markets. These products are used in a range of applications from cosmetics to the prescription treatment of conditions like dermatitis, psoriasis and eczema.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NYSE:IG
- CUSIP: N/A
- Web: N/A
- 50 Day Moving Avg: $7.71
- 200 Day Moving Avg: $7.24
- 52 Week Range: $4.75 - $12.05
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 64.00
- P/E Growth: 0.00
- Average Volume: 583,158 shs.
Frequently Asked Questions for IGI Laboratories (NYSE:IG)
What is IGI Laboratories' stock symbol?
IGI Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "IG."
How were IGI Laboratories' earnings last quarter?
IGI Laboratories, Inc. (NYSE:IG) posted its earnings results on Thursday, October, 22nd. The company reported ($0.02) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.05) by $0.03. The firm had revenue of $11.60 million for the quarter, compared to analysts' expectations of $9.36 million. The company's quarterly revenue was up 73.1% compared to the same quarter last year. View IGI Laboratories' Earnings History.
Who are some of IGI Laboratories' key competitors?
Some companies that are related to IGI Laboratories include HDFC Bank Limited (HDB), Berkshire Hathaway (BRK.B), Berkshire Hathaway (BRK.A), Alibaba Group Holding Limited (BABA), Johnson & Johnson (JNJ), Exxon Mobil Corporation (XOM), J P Morgan Chase & Co (JPM), Bank of America Corporation (BAC), Wells Fargo & Company (WFC), Wal-Mart Stores (WMT), Royal Dutch Shell PLC (RDS.B), Royal Dutch Shell PLC (RDS.A), Visa (V), Anheuser-Busch Inbev SA (BUD), Procter & Gamble Company (The) (PG), Chevron Corporation (CVX), AT&T (T) and Pfizer (PFE).
How do I buy IGI Laboratories stock?
Shares of IGI Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IGI Laboratories' stock price today?
MarketBeat Community Rating for IGI Laboratories (NYSE IG)MarketBeat's community ratings are surveys of what our community members think about IGI Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of IGI Laboratories stock can currently be purchased for approximately $7.68.
Consensus Ratings for IGI Laboratories (NYSE:IG) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for IGI Laboratories (NYSE:IG)
Analysts' Ratings History for IGI Laboratories (NYSE:IG)
(Data available from 10/19/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/23/2015||Roth Capital||Reiterated Rating||Buy||N/A|
Earnings History for IGI Laboratories (NYSE:IG)Earnings History by Quarter for IGI Laboratories (NYSE IG)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|10/22/2015||Q315||($0.05)||($0.02)||$9.36 million||$11.60 million||View||Listen|
|7/23/2015||Q2||($0.08)||($0.04)||$7.63 million||$8.90 million||View||Listen|
|3/2/2015||Q414||$0.06||$0.09||$11.88 million||$13.70 million||View||N/A|
|11/13/2012||Q312||($0.04)||$2.11 million||$1.98 million||View||N/A|
Earnings Estimates for IGI Laboratories (NYSE:IG)
Current Year EPS Consensus Estimate: $-0.08 EPS
Next Year EPS Consensus Estimate: $0.12 EPS
Dividend History for IGI Laboratories (NYSE:IG)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for IGI Laboratories (NYSE:IG)Insider Trades by Quarter for IGI Laboratories (NYSE:IG)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/1/2015||Jason Grenfell-Gardner||CEO||Sell||84,048||$7.94||$667,341.12|| |
|4/30/2015||James C Gale||Director||Buy||30,000||$5.04||$151,200.00|| |
|3/5/2015||Sciences Opportunities Fu Life||Major Shareholder||Sell||2,000,000||$9.95||$19,900,000.00|| |
|9/2/2014||Sciences Opportunities Fu Life||Major Shareholder||Sell||2,000,000||$6.45||$12,900,000.00|| |
|8/27/2014||Sciences Opportunities Fu Life||Major Shareholder||Sell||3,000,000||$6.20||$18,600,000.00|| |
|8/22/2014||James C Gale||Director||Buy||5,000||$5.90||$29,500.00|| |
|8/4/2014||Jason Grenfell-Gardner||CEO||Sell||66,828||$5.85||$390,943.80|| |
|6/9/2014||Joyce Erony||Director||Sell||17,500||$5.48||$95,900.00|| |
|8/6/2013||Michael B Hemric||Director||Buy||50,000||$1.48||$74,000.00|| |
|5/24/2013||Jason Grenfell-Gardner||CEO||Buy||3,500||$1.55||$5,425.00|| |
|3/13/2013||James C Gale||Director||Buy||10,000||$1.33||$13,300.00|| |
|3/12/2013||Michael B Hemric||Director||Buy||20,637||$1.19||$24,558.03|| |
|8/14/2012||Jason Grenfell-Gardner||CEO||Buy||10,000||$1.15||$11,500.00|| |
Headline Trends for IGI Laboratories (NYSE:IG)
Latest Headlines for IGI Laboratories (NYSE:IG)
IGI Laboratories (IG) Chart for Thursday, October, 19, 2017